Paying for On-Patent Pharmaceuticals
نویسندگان
چکیده
In this article we propose a new approach to pricing for patent-protected (on-patent) pharmaceuticals. We describe and define limit pricing as a method for drug companies to maximize revenue for their investment by offering budget-neutral pricing to encourage early adoption by payers. Under this approach, payers are incentivized to adopt innovative but expensive drugs more quickly if drug companies provide detailed analyses of the net impact of the new pharmaceutical upon total health budgets. For payers to adopt use of a new pharmaceutical, they would require objective third-party evaluation and pharmaceutical manufacturer accountability for projected outcomes efficacy of their treatments on population health. The pay for outcomes underpinning of this approach falls within the wider aspirations of health reform.
منابع مشابه
Brand V/S Generic- Value Based Pricing for Pharmaceuticals in India
The pharmaceuticals in its widen scope means drugs, diagnostics and other commodities that are used to treat disease, manage the condition along with tools and system which are used to diagnose the disease [1]. The pharmaceuticals are the result of extensive research effort which is usually governed by the Intellectual Property Rights (IPR). The IPR is protected by registering the pharmaceutica...
متن کاملDoes Foreign Patent Protection Increase the United States’ Trade of Pharmaceuticals with Developing Countries?
The United States has been pushing for foreign patent protection through free trade agreements and the World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). A gravity model using panel data from 1993 to 2007 suggests that foreign patent protection has not significantly increased the United States’ trade of pharmaceuticals. Other factors are stron...
متن کاملLonger Patents For Lower Imitation Barriers : The 1984 Drug Act
On September 24, 1984, President Reagan signed into law the Drug Price Competition and Patent Term Restoration Act of 1984. This law, the first change in United States patent terms since 1861, restores part of the patent life lost during the premarket regulatory process for new pharmaceuticals (and also for medical devices and food additives). A second major provision of the law facilitates the...
متن کاملFinancial incentives , state dependence , and heterogeneity : diffusion of post - patent pharmaceuticals ∗ April 27 , 2009 Toshiaki
The speed of diffusion of post-patent pharmaceuticals has important implications both on the reduction of pharmaceutical expenditures and on the incentive to innovate. Exploiting rich micro-panel data, I study the diffusion of post-patent pharmaceuticals. I find that doctors on average fail to internalize patient costs and strong state dependence exists in prescription choices. These explain wh...
متن کاملEstimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India.
Under the Agreement on Trade-Related Intellectual Property Rights, the World Trade Organization members are required to enforce product patents for pharmaceuticals. In this paper we empirically investigate the welfare effects of this requirement on developing countries using data for the fluoroquinolones subsegment of the systemic anti-bacterials segment of the Indian pharmaceuticals market. Ou...
متن کامل